Patient-centric Care Approach in the Management of Overactive Bladder (OAB)
December 13th 2023Michael J. Kennelly, MD, FPMRS, FACS, joined by Kevin D. Benson, MD, MS and Karyn S. Eilber, MD, leads a comprehensive Urology Times® Viewpoints discussion on patient-centric management of overactive bladder (OAB). They cover an overview of OAB, standard care treatments, device and procedural advancements, and practical considerations for patient-centric care. The session delves into diagnostic assessments, symptom presentations, impact on quality of life, guideline recommendations for treatment, and the clinical benefits and limitations of standard pharmacological treatments. The experts also discuss the role of device-based therapies like sacral neuromodulation and intravesical botulinum toxin type A, focusing on patient eligibility, clinical experiences, and managing post-procedure care. They share insights on adapting procedures to enhance patient comfort, managing expectations, and the importance of follow-up care, providing valuable advice for enhancing patient experiences in OAB management.
Emerging Therapeutic Approaches in High- and Intermediate- Risk NMIBC
December 13th 2023This Urology Times® Viewpoints video series provides a detailed exploration of non-muscle invasive bladder cancer (NMIBC), led by Dr. Sam Chang of Vanderbilt University and featuring expert panelists Dr. Gary Steinberg, Dr. Sandip Prasad, Dr. Mark Tyson, and Dr. Roger Lee filmed at Society for Urological Oncology (SUO) 2023. The series delves into the nuances of staging and grading NMIBC, emphasizing the differences between low-grade and high-grade tumors and their implications for treatment strategies. The discussion spans a range of topics including the management of high-risk and intermediate-risk NMIBC, the challenges in treating the BCG unresponsive population, and the examination of new therapeutic advances and clinical trials, such as N803, TAR 200, and Cretostimogene Grenadenorepvec, underscoring the importance of personalized care in NMIBC treatment.
Management of Advanced Prostate Cancer in Urology: Update on Androgen Receptor Inhibitors
November 30th 2021Neal Shore, MD, FACS; Bobby Liaw, MD; Vivek K. Narayan, MD, MS; and Ashley E. Ross, MD, PhD, share key insights on advances in the use of androgen receptor inhibitors (ARIs) and discuss the urologist’s role in managing patients with mCSPC and nmCRPC.